Information sharing - the most valuable benefit expected from serialization?
NEXUS 17 attendees claim the greatest serialization challenge thus far has been line vendors’ inability to deliver a solution on time and within scope.
TraceLink has announced new industry findings from its annual conference, NEXUS 17. Interactive polling results indicated that the majority of pharmaceutical supply chain professionals (78% of attendees), believe that end-to-end visibility of pharmaceutical products in the supply chain is achievable within the next 5 years, with information sharing between trading partners cited as one of the most valuable business benefits.
At NEXUS 17 in Barcelona earlier this month, TraceLink introduced its strategy for leveraging the industry’s only digital supply chain network to facilitate a new era of real-time information sharing, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients. The first application unveiled within this road map, the Pharmacy Compliance and Digital Information Platform, enables any EU pharmacy to easily comply with verification and decommissioning requirements under the Falsified Medicines Directive (FMD), while simultaneously delivering a real-time dashboard for insights into pharmacy operations and enabling a direct communication channel from the pharmaceutical manufacturer to the pharmacy.
NEXUS 17 drew more than 200 pharmaceutical supply chain professionals and business leaders, representing over 120 unique companies from 21 different countries. The conference included educational content from 30 speakers, including esteemed keynote speaker, Dr Bertalan Mesko – “The Medical Futurist” and experts from Sanofi, Santen, Recipharm, Tjoapack, MIT and the European Medicines Verification Organisation (EMVO).
“There is tremendous value in connecting companies and trade partners together in an educational forum, allowing everyone to equally learn from collective wisdom. This year, NEXUS truly showcased the power of the network in the pharmaceutical supply chain – demonstrated through inspirational keynotes, dynamic breakout and roundtable discussions, and high attendee engagement during the networking sessions,” said Shabbir Dahod, president and CEO, TraceLink.
“As serialization deadlines fall into place, now is the time to leverage the foundation of an integrated network to enhance real-time communication and information exchange between all of the partners in the supply chain. By enabling the flow of serialization data between over 260,000 trade partners on our network, TraceLink is the only provider that can deliver the next step of capabilities by taking information and moving it end-to-end across the supply chain."
NEXUS 17 attendees also responded to questions about serialization preparation, challenges and trade partner readiness, indicating the following:
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance